Incyte (INCY) Cash from Restructuring (2010 - 2011)
Incyte (INCY) posted Cash from Restructuring of -$108000.0 for Q4 2011, down 183.72% on a QoQ basis from $129000.0 in Q2 2011, and down 640.0% year-over-year from $20000.0 in Q4 2010.
Incyte (INCY) Cash from Restructuring (2010 - 2011) Analysis & Trends
Incyte's Cash from Restructuring history runs 2 years deep, the most recent figure standing at -$108000.0 for Q4 2011.
- Quarterly Cash from Restructuring fell 640.0% year-over-year to -$108000.0 in Q4 2011, while the trailing twelve-month figure through Dec 2011 was -$88000.0 (up 76.78% YoY) and the FY2011 annual result came in at -$88000.0, up 76.78% from the prior year.
- Cash from Restructuring was -$108000.0 for Q4 2011 at Incyte, down from $129000.0 in the prior quarter.
- Across five years, Cash from Restructuring topped out at $129000.0 in Q2 2011 and bottomed at -$145000.0 in Q2 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Incyte | 23.33 Bn | 19.32 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | -108,000.00 |
| Jun 30, 2011 | 129,000.00 |
| Mar 31, 2011 | -109,000.00 |
| Dec 31, 2010 | 20,000.00 |
| Sep 30, 2010 | -139,000.00 |
| Jun 30, 2010 | -145,000.00 |
| Mar 31, 2010 | -115,000.00 |